Comparison of Efficacy of Romosozumab With Denosumab and Risedronate in Patients Newly Initiating Glucocorticoid Therapy - Takeaways - MDSpire

Comparison of Efficacy of Romosozumab With Denosumab and Risedronate in Patients Newly Initiating Glucocorticoid Therapy

  • By

  • Mai Kawazoe

  • Kaichi Kaneko

  • Shotaro Masuoka

  • Soichi Yamada

  • Zento Yamada

  • Sei Muraoka

  • Karin Furukawa

  • Hiroshi Sato

  • Eri Watanabe

  • Keiko Koshiba

  • Izumi Irita

  • Miwa Kanaji

  • Takahiko Sugihara

  • Junko Nishio

  • Toshihiro Nanki

  • November 18, 2024

  • 0 min

Share

  • 1

    Romosozumab (ROMO) significantly increased lumbar spine bone mineral density (BMD) compared to denosumab (DMAb) and bisphosphonates (BP) in glucocorticoid-treated patients.

  • 2

    The study involved patients with rheumatic diseases starting glucocorticoid therapy, randomly assigned to receive ROMO, DMAb, or BP.

  • 3

    After 12 months, the median percent change in lumbar spine BMD was highest in the ROMO group at 8.6%, compared to 3.3% for DMAb and -0.4% for BP.

  • 4

    Bone turnover markers showed slight increases in the ROMO group, while decreases were observed in all groups, indicating varied effects on bone metabolism.

  • 5

    The findings suggest that ROMO is an effective treatment option for glucocorticoid-induced osteoporosis (GIOP), warranting further investigation.

Original Source(s)

Comparison of Efficacy of Romosozumab With Denosumab and Risedronate in Patients Newly Initiating Glucocorticoid Therapy

  • by Mai Kawazoe, Kaichi Kaneko, Shotaro Masuoka, Soichi Yamada, Zento Yamada, Sei Muraoka, Karin Furukawa, Hiroshi Sato, Eri Watanabe, Keiko Koshiba, Izumi Irita, Miwa Kanaji, Takahiko Sugihara, Junko Nishio, Toshihiro Nanki

  • November 18, 2024

Related Content

MAFLD is associated with lower bone mineral density in patients with type 2 diabetes: an exploratory cross-sectional analysis of a potential indirect association with HOMA-IR

Comparative efficacy and safety of odanacatib, abaloparatide, denosumab, teriparatide, and bisphosphonates for male osteoporosis: a systematic review and network meta-analysis

Lower odds of prevalent vertebral fractures with b/tsDMARD use among rheumatoid arthritis patients in clinical remission: a retrospective observational study